Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in ALS
NCT02469896Phase 2Completed
- Sponsor
- Barrow Neurological Institute
- Start
- Nov 2015
- Primary completion
- Jul 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in amyotrophic lateral sclerosis (ALS), sponsored by Barrow Neurological Institute. Started Nov 2015; status: completed.
02
Drugs
tocilizumab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02469896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02469896.